JM
Insider
John S. Montalbano
DirectorJohn S. Montalbano (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in AbCellera Biologics Inc. (ABCL). Across 2 priced purchase filings, the average 21-session return was +3.2% from execution and +3.2% from disclosure (delay-adjusted; derived). The largest single filing was $178K of ABCL (50,000 sh × $3.57, as filed), executed Nov 26 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+3.2%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+3.2%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$289K
shares × price, as filed
Last traded
Aug 18
Filed Aug 18
Median ADV $89.1M across their filed names
Open performance→Volume by month
Buys $429K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
ABCLRecent filings
ABCLPURCHASE
AbCellera Biologics Inc.
View filing →
$110K10,000 sh × $11.03
Exec Aug 18
Filed Aug 18 · 2:45 PM ET ABCLPURCHASE AbCellera Biologics Inc. View filing → $178K
50,000 sh × $3.57
Exec Nov 26 2025
Filed Nov 26 2025 · 2:58 PM ET ABCLPURCHASE AbCellera Biologics Inc. View filing → $140K
60,000 sh × $2.34
Exec Mar 6 2025
Filed Mar 7 2025 · 5:30 PM ET